The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

Medically reviewed by Femi Aremu, PharmD Nicotinamide adenine dinucleotide (NAD+) is a natural compound in your body. It ...

The FDA has approved Soliris the first-ever treatment for children with generalized myasthenia gravis gMG offering new hope in pediatric neuromuscular care Learn more!

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.